HomepageTRVN • OTCMKTS
add
Trevena Inc
Vorige slotkoers
$Â 0,91
Jaar-range
$Â 0,73 - $Â 2,49
Beurswaarde
786,05K USD
Gem. volume
1,29K
Koers/winst
-
Dividendrendement
-
Primaire beurs
OTCMKTS
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(USD) | sep 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 283,00K | 57,22% |
Bedrijfskosten | 5,75Â mln. | -34,94% |
Netto inkomsten | -4,94Â mln. | 37,72% |
Netto winstmarge | -1,75K | 60,39% |
Winst per aandeel | — | — |
EBITDA | -5,48Â mln. | 37,30% |
Effectief belastingtarief | -0,61% | — |
Balans
Totale activa
Totale passiva
(USD) | sep 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 13,46Â mln. | -61,48% |
Totale activa | 19,19Â mln. | -57,49% |
Totale passiva | 42,50Â mln. | 2,20% |
Totaal aandelenvermogen | -23,31 mln. | — |
Uitstaande aandelen | 863,79K | — |
Koers-boekwaardeverhouding | -0,03 | — |
Rendement op activa | -66,19% | — |
Rendement op kapitaal | -87,77% | — |
Kasstroom
Nettomutatie in liquide middelen
(USD) | sep 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -4,94Â mln. | 37,72% |
Operationele kasstroom | -4,50Â mln. | 49,55% |
Kasstroom uit beleggingen | — | — |
Kasstroom uit financiering | 1,68Â mln. | -89,35% |
Nettomutatie in liquide middelen | -2,82Â mln. | -141,18% |
Vrije kasstroom | -3,05Â mln. | 57,99% |
Over
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week.
Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
Opgericht
2007
Hoofdvestiging
Website
Werknemers
23